Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | ABAT | P80404 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176609 | 0.87 | ALDH1A1 (0.45) | ESR1ESR2CA2KDM4EALDH1A1 | |
| SCHEMBL4405623 | 0.85 | ESR1 (0.70) | ESR1ESR2ABATCA2TMEM97 | |
| SCHEMBL320687 | 0.84 | CALM1 (0.44) | ESR1ESR2ALDH1A1ADRA2AKMT2A | |
| SCHEMBL36454 | 0.84 | ESR1 (1.00) | ESR1ESR2KEAP1ABATCA2 | |
| SCHEMBL2969737 | 0.84 | ESR1 (1.00) | ESR1ESR2KEAP1ABATCA2 | |
| SCHEMBL27483116 | 0.83 | ESR1 (0.67) | ESR1ESR2ABATCA2TMEM97 | |
| SCHEMBL9061039 | 0.81 | ESR1 (0.56) | ESR1ESR2CA2TMEM97SIGMAR1 | |
| SCHEMBL8791387 | 0.78 | CA1 (0.71) | ESR1ESR2CA2KDM4EALDH1A1 | |
| SCHEMBL7911223 | 0.76 | ESR1 (0.56) | ESR1ESR2KEAP1ABATCA2 | |
| SCHEMBL28775338 | 0.76 | ENPP2 (0.50) | CA2KDM4EALDH1A1TAAR1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820087-A | Preparation method of bisphenol A diglycerol ether compound | 中国石油化工股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| EP-0724583-B1 | PYRIDAZINO QUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-13 | — | — | EP | claimed |
| CN-117820087-A | Preparation method of bisphenol A diglycerol ether compound | 中国石油化工股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| US-5744471-A | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 1998-04-28 | — | — | US | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0790996-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| CN-1150589-A | New sulfuric acid esters of sugar alcohols | HOFFMANN LA ROCHE (CH) | 1997-05-28 | — | — | CN | disclosed |
| EP-0745074-A1 | 4-AMINO DERIVATIVES OF MYCOPHENOLIC ACID WITH IMMUNOSUPPRESSANT ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0724583-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996015127-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| WO-1995011244-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | ESR1 819/4885ESR2 467/4885KEAP1 2825/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | ESR1 819/4885ESR2 467/4885KEAP1 2825/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | ESR1 795/4885ESR2 660/4885KEAP1 2803/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | ESR1 819/4885ESR2 467/4885KEAP1 2825/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | ESR1 698/4885ESR2 540/4885KEAP1 2758/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | ESR1 801/4885ESR2 471/4885KEAP1 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.